Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Adenocarcinoma × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Wounds and Injuries 1 Ulcer 1 Skin Ulcer 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Chronic Pain 1 Cancer Pain 1 Adenocarcinoma 1

Interventions

Nivolumab 2 Gemcitabine 2 temoporfin 1 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 devimistat 1 dalotuzumab 1 bemarituzumab 1 belinostat 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Oxaliplatin 1 Morphine 1 Methadone 1 Leucovorin 1 Ipilimumab 1 Interviews as Topic 1 Injections 1 Immunotherapy 1 Heavy Ion Radiotherapy 1 Fluorouracil 1 Cisplatin 1 Brachytherapy 1 Biopsy 1 Bevacizumab 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05325164 2022-12-05

METHADOPT

Ottawa Hospital Research Institute

Phase 3 Withdrawn

Cancer Pain, Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡